What anesthesia considerations are recommended for a patient on methotrexate undergoing elective surgery?

Anesthesia Considerations for Methotrexate

Methotrexate can be safely continued through the perioperative period in patients with rheumatoid arthritis and related rheumatic diseases undergoing elective surgery. 1

Key Perioperative Management Recommendations

Continue Methotrexate Through Surgery

The strongest guideline evidence supports continuing methotrexate without interruption for elective orthopedic surgery in RA patients 1. This recommendation is based on four studies showing:

• No increase in postoperative complications when methotrexate was continued (mean dose 10 mg/week) 1
• Significantly fewer RA disease flares in patients who continued versus stopped methotrexate 1
• No association with wound morbidity (p=0.84) in multivariate analysis 1
• One contrasting prospective cohort study showed 30% infection rate with continued methotrexate versus 0% when stopped, but this was outweighed by higher-quality RCT evidence 1

For severe SLE patients: Continue methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus through the surgical period 2, 3

For non-severe SLE patients: Withhold these medications 1 week prior to surgery 2, 3

Important Caveats and Limitations

The evidence base has critical gaps:

• Studies focused exclusively on elective orthopedic surgery - no data exists for non-orthopedic or emergency procedures 1
• Most patients received low-dose methotrexate (5-10 mg/week) - safety at higher doses (>20 mg/week) is not established 1
• No data addresses patients with significant comorbidities (renal failure, active infection, diabetes) 4

Specific Contraindications to Continuing Methotrexate

Stop methotrexate if:

• Renal failure present (creatinine clearance <60 mL/min) 5
• Active sepsis or infection 6
• Emergency/urgent surgery (insufficient time for assessment)
• Non-orthopedic major surgery (extrapolate cautiously - no direct evidence)

Preoperative Laboratory Monitoring

Within 1-1.5 months before surgery, verify:

• ALT/AST (should be <3x upper limit of normal) 1
• Creatinine and calculated creatinine clearance 1
• Complete blood count 1

If abnormalities exist, delay elective surgery until values normalize or methotrexate is appropriately adjusted 1.

Anesthetic Technique Considerations

No specific anesthetic technique restrictions are documented in the guidelines. However, apply standard principles:

• Neuraxial anesthesia (spinal/epidural) can be performed safely - the evidence base includes patients who received these techniques 1
• Ensure adequate hydration status perioperatively, as methotrexate requires renal clearance
• Avoid nephrotoxic agents when possible (NSAIDs, aminoglycosides) to prevent methotrexate accumulation
• Monitor for mucositis or stomatitis which may complicate airway management if severe

Postoperative Resumption

Resume methotrexate at the regular weekly dose once:

• Wound shows evidence of healing (typically ~14 days for biologics, but methotrexate continuation means no interruption needed) 3
• No clinical evidence of surgical site infection
• No systemic infection present

For patients in whom methotrexate was stopped (non-RA indications or surgeon preference despite evidence), restart when wound healing is adequate and no infection is present.

Drug Interactions Relevant to Anesthesia

Methotrexate increases toxicity risk when combined with:

• NSAIDs - reduce renal clearance of methotrexate, increasing toxicity risk; use cautiously for postoperative analgesia
• Proton pump inhibitors - may increase methotrexate levels
• Penicillins - reduce renal tubular secretion of methotrexate

Folic acid supplementation (≥5 mg/week) should be continued perioperatively as it reduces GI and hepatic toxicity without reducing efficacy 1.

Disease Flare Prevention

The primary benefit of continuing methotrexate is preventing disease flares, which occurred significantly more frequently when methotrexate was stopped 1. Disease flares can:

• Delay mobilization and rehabilitation
• Increase pain and opioid requirements
• Prolong hospital stay
• Worsen functional outcomes

Special Populations

Pregnancy: Methotrexate must be stopped ≥3 months before planned pregnancy in both men and women 1. This is non-negotiable for elective surgery in reproductive-age patients.

Elderly patients: No specific dose adjustments for anesthesia, but standard geriatric precautions apply. Methotrexate dosing may need adjustment based on renal function.

Common Pitfalls to Avoid

1. Do not reflexively stop methotrexate "to be safe" - evidence shows this increases flare risk without reducing infection risk in appropriate patients 7, 8
2. Do not extrapolate orthopedic surgery data to high-risk procedures (cardiac, neurosurgery, transplant) without individualized risk assessment
3. Do not ignore renal function - methotrexate toxicity escalates rapidly with renal impairment
4. Do not forget folic acid - ensure patients continue supplementation throughout perioperative period